Most patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage of
disease. Until recently, systemic treatment options that showed survival benefits in HCC …

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth
most common cancer among men in South Korea, where the prevalence of chronic hepatitis …

Immunotherapies aimed at strengthening immune effector responses against malignant
cells are growing at exponential rates. Alongside, the impressive benefits obtained by …

Hepatocellular carcinoma (HCC) is characterized by poor outcome and shows limited drug-
response in clinical trials. Tumor immune microenvironment (TIME) exerts a strong selection …

Tumor recurrence rate after surgery or ablation of hepatocellular carcinoma (HCC) is as high
as 70%. However, there are no widely accepted adjuvant therapies; therefore, no treatment …

Chimeric antigen receptor (CAR) T cell is a novel approach, which utilizes anti-tumor
immunity for cancer treatment. As compared to the traditional cell-mediated immunity, CAR-T …

Checkpoint inhibitor (CPI) based immunotherapy (ie, anit-CTLA-4/PD-1/PD-L1 antibodies)
can effectively prolong overall survival of patients across several cancer types at the …

Primary liver cancer, mainly hepatocellular carcinoma (HCC), is the sixth most diagnosed
cancer and third leading cause of cancer-related death globally. Recently, immunotherapies …

Although many approaches have been used to treat hepatocellular carcinoma (HCC), the
clinical benefits remain limited, particularly for late stage HCC. In recent years, studies have …

Natural killer (NK) cells are lymphoid cells of innate immunity that take important roles in
immune surveillance. NK cells are considered as a bridge between innate and adaptive …